UBS sees 2.2% decline in advisor headcount during the past 12 months.
UBS wealth management in the Americas continues to see a decline in its overall team of financial advisors,…
Switzerland tops the European Innovation Scoreboard once again
Europe’s innovation performance continues to improve, with the EU’s overall score rising by 11.6 percentage points since 2019,…
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 Clinically meaningful improvements of…
Novartis reports positive results from Phase III ALIGN trial for IgAN
Novartis has announced final results from the Phase III ALIGN study, highlighting that Vanrafia (atrasentan) slows kidney function…
Oil Production Attributable to Glencore in Cameroon Fell 14% in Early 2026
Oil production attributable to Glencore in Cameroon declined during the first quarter of 2026, reflecting weaker output across…
Novartis’ Q1 sales miss hints at industry’s utilisation of M&A remedies
A weak Q1 for Novartis that was heavily impacted by generics erosion showcases that the billions of dollars…
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
– Novartis today announced final two-year results from the Phase III APPLAUSE‑IgAN study of Fabhalta® (iptacopan) in IgA…
UBS Upgrades Palantir, Sees Buying Opportunity After Steep Decline
UBS upgrades Palantir to Buy with a $180 target after a 35% stock pullback, citing a key defense…
Geneva, Two Negotiations and One Shared Loser
Islam Times – The coincidence of two sensitive negotiations in Geneva — the Iran–US nuclear talks and consultations…
BAE Systems posts better-than-expected FY profit growth, Glencore FY profits decline on weak coal performance
LONDON PRE-OPEN The FTSE 100 was expected to open 26.2 points higher ahead of the bell on Wednesday,…
Glencore FY profits decline as coal weakness offsets metals strength
Mining giant Glencore posted a decline in full‑year profits on Wednesday, as record copper prices were unable to…
Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
In ALIGN study, Vanrafia (atrasentan) showed positive differencein eGFR change from baseline vs. placebo at Week 136, 4…